News

2023/10/25
- Press release
AlphaNavi Pharma Exercises Option Regarding DSP-3905 under Development for Neuropathic Pain from Sum …
Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomu …
2023/03/01
- Press release
Series B Round of Financing
AlphaNavi Pharma Inc. (“AlphaNavi”) (Head Office: Osaka, Japan; President and CEO: Yoshihiro Oyamada) announce …
2021/05/11
- information
AlphaNavi Pharma Inc., Announces Initiation of a Phase 1/2 Clinical Trial of ANP-230 in Patients wit …
AlphaNavi Pharma Inc. (Headquarter: Sakyo-ku, Kyoto, Japan; CEO: Yoshihiro Oyamada) today announced the initia …
2020/06/05
- information
AlphaNavi Pharma Inc., was introduced in the case study of leading university-originated venture bus …
AlphaNavi Pharma Inc., (Head Office: Kyoto, Japan; CEO: Yoshihiro Oyamada), which is a start-up company to dev …
2020/05/12
- information
“Study of a novel drug for the familial episodic infantile limb pain syndrome” was chosen by AMED as …
AlphaNavi Pharma Inc., (Head Office: Kyoto, Japan; CEO: Yoshihiro Oyamada; hereinafter referred to as “A …